Advances In™ PAH Associated with Congenital Heart Disease (PAH-CHD): Designing New Treatment Strategies Backed by Better Disease Understanding

Target Audience
This online educational activity is directed toward cardiologists, pulmonologists, NPs, PAs, and RNs. Additional healthcare professionals involved in the management and treatment of patients with PAH-CHD will also be invited to participate in this activity.

Program Overview
Pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD) is a lethal and progressive disease in which prostacyclin, nitric oxide, and endothelin-1 pathways are disturbed and contribute to the pathophysiology of this disease. Undiagnosed or delayed diagnosis of PAH might lead to Eisenmenger syndrome (ES). Screening for PAH in patients with CHD and timely diagnosis can facilitate prompt treatment; promising medical therapies have recently been approved for the management of patients with PAH-CHD, bringing about hope for improved hemodynamics, exercise capacity, quality of life, and possibly, survival for this patient population.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Describe the latest theories of PAH-CHD pathogenesis
Discuss advances in the diagnostic and prognostic assessment of PAH-CHD
Determine appropriate treatment strategies for individual patients based on disease pathophysiology, disease severity, and risk assessments